Rxivist logo

Rxivist.org combines preprints from bioRxiv and medRxiv with data from Twitter to help you find the papers being discussed in your field.
Currently indexing 172,981 papers from 714,387 authors.

Most downloaded biology preprints, all time

Results 1 through 20 out of 644

in category oncology

 

1: The impact of the coronavirus disease 2019 (COVID-19) outbreak on cancer practice in Japan: using an administrative database

Hisashi Itoshima, Yuka Asami et al.

12,676 downloads (posted 18 Nov 2020)

Background: Recent researches reported the impact of the coronavirus disease 2019 (COVID - 19) pandemic on the clinical practice of specific type cancers. The aim of this study was to reveal the impact of the COVID-19 outbreak on the clinical practice of various cancers. Methods: We included hospitalized patients aged 18 years or older diagnosed between July 2018 and June 2020 with one of the top 12 most common cancers in Japan (colon/rectum, lung, gastric, breast, bladder & urinary tract, pancreas, non-Hodgkin lymphoma, liver, prostate, esophagus, uterus, and gallbladder & biliary tract) using Diagnostic Procedure Combination data, an administrative database in Japan. The intervention was defined April 2020 based on a declaration of emergency from Japanese government. The change volume of number of monthly admissions with each cancer was tested by interrupted time series (ITS) analysis, and monthly cases with radical surgery or chemotherapy for each cancer were descripted. Results: 403,344 cases were included during the study period. The most common cancer was colon/rectum (20.5%), followed by lung (17.5%). In almost cancer cases, the number of admissions decreased in May 2020. In particular, colorectal, lung, gastric, breast, uterine, or esophageal cancer cases decreased by over 10%. The number of admissions with surgery or chemotherapy decreased in colorectal, lung, gastric, breast, uterine, or esophageal cancer. ITS analysis indicated that cases with gastric or esophageal cancer were affected more than other type of cancer. Conclusions: The COVID-19 outbreak has a negative impact on the number of admission cases with cancer; the magnitude of impact varied by cancer diagnosis.

https://rxivist.org/papers/105342
https://doi.org/10.1101/2020.11.18.20233700

2: Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

Leticia Monin-Aldama, Adam G. Laing et al.

5,667 downloads (posted 17 Mar 2021)

Background: The efficacy and safety profile of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in immunocompromised patient populations. Patients with a known cancer diagnosis were hitherto excluded from trials of the vaccines currently in clinical use. Methods: This study presents data on the safety and immune efficacy of the BNT162b.2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malign...

https://rxivist.org/papers/133816
https://doi.org/10.1101/2021.03.17.21253131

3: Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR

Xinran Ma, Lura Long et al.

5,059 downloads (posted 18 Mar 2020)

Background and ObjectiveThe Surveillance, Epidemiology, and End Results Program (SEER) program and the National Program of Cancer Registries (NPCR), are authoritative sources for population cancer surveillance and research in the US. An increasing number of recent oncology studies are based on the electronic health record (EHR)-derived de-identified databases created and maintained by Flatiron Health. This report describes the differences in the originating sources and data development processes, and compares baseline d...

https://rxivist.org/papers/107524
https://doi.org/10.1101/2020.03.16.20037143

4: Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients

Matt Williams, Ella Mi et al.

4,923 downloads (posted 20 Mar 2020)

The SARS-CoV-2 (COVID-19) novel corona virus represents a significant health risk, particularly in older patients. Cancer is one of the leading causes of death in most rich countries, and delivering chemotherapy may be associated with increased risk in the presence of a pandemic infection. Estimating this risk is crucial in making decisions about balancing risks and benefits from administering chemotherapy. However, there are no specific data about chemotherapy risks per se. Here we develop a simple model to estimate th...

https://rxivist.org/papers/107598
https://doi.org/10.1101/2020.03.18.20038067

5: Collateral damage: the impact on cancer outcomes of the COVID-19pandemic

Amit Sud, Michael E. Jones et al.

4,865 downloads (posted 24 Apr 2020)

Background: Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival. Methods: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of three months and six months and periods of disruption of one year and two years. Using healthcare resou...

https://rxivist.org/papers/109256
https://doi.org/10.1101/2020.04.21.20073833

6: The Tumor Profiler Study: Integrated, multi-omic, functional tumor profiling for clinical decision support

Anja Irmisch, Ximena Bonilla et al.

3,018 downloads (posted 14 Feb 2020)

Recent technological advances allow profiling of tumor samples to an unparalleled level with respect to molecular and spatial composition as well as treatment response. We describe a prospective, observational clinical study performed within the Tumor Profiler (TuPro) Consortium that aims to show the extent to which such comprehensive information leads to advanced mechanistic insights of a patients tumor, enables prognostic and predictive biomarker discovery, and has the potential to support clinical decision making. Fo...

https://rxivist.org/papers/106901
https://doi.org/10.1101/2020.02.13.20017921

7: Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Darci Phillips, Magdalena Matusiak et al.

2,273 downloads (posted 08 Dec 2020)

Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T cell lymphoma (CTCL) patients enrolled in a clinical trial of pembrolizumab therapy. Clinical response was not associated with the frequency of tumor-infiltrating T cell subsets, but rather with striking differences in the spatial organization and functional immune state of the tumor mi...

https://rxivist.org/papers/120712
https://doi.org/10.1101/2020.12.06.20244913

8: Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency

Alvina G Lai, Laura Pasea et al.

2,268 downloads (posted 01 Jun 2020)

Background: Cancer and multiple non-cancer conditions are considered by the Centers for Disease Control and Prevention (CDC) as high risk conditions in the COVID-19 emergency. Professional societies have recommended changes in cancer service provision to minimize COVID-19 risks to cancer patients and health care workers. However, we do not know the extent to which cancer patients, in whom multi-morbidity is common, may be at higher overall risk of mortality as a net result of multiple factors including COVID-19 infectio...

https://rxivist.org/papers/111671
https://doi.org/10.1101/2020.05.27.20083287

9: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson et al.

2,207 downloads (posted 30 Mar 2020)

PurposeThe oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking. MethodsWe enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between ...

https://rxivist.org/papers/107970
https://doi.org/10.1101/2020.03.26.20044305

10: A systematic review and meta-analysis of cancer patients affected by a novel coronavirus

Bhanu Prasad Venkatesulu, Viveksandeep Thoguluva Chandrasekar et al.

2,084 downloads (posted 29 May 2020)

Background Cancer patients with COVID-19 disease have been reported to have double the case fatality rate of the general population. Materials and methods A systematic search of PubMed/MEDLINE, Embase, Cochrane Central, Google Scholar, and MedRxiv was done for studies on cancer patients with COVID-19. Pooled proportions were calculated for categorical variables. Odds ratio and forest plots were constructed for both primary and secondary outcomes. The random-effects model was used to account for heterogeneity between stu...

https://rxivist.org/papers/111521
https://doi.org/10.1101/2020.05.27.20115303

11: SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan

Jing Yu, Wen Ouyang et al.

2,010 downloads (posted 25 Feb 2020)

In December 2019, an outbreak of atypical pneumonia known as 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, China. This new type of pneumonia is characterized by rapid human-to-human transmission. Among the different disease types, cancer patients are often recalled to the hospital for treatment and disease surveillance, and the majority of cancer treatments such as chemotherapy and radiotherapy are immunosuppressive. This prompts us to consider if cancer patients were at an elevated risk of SARS-CoV-2 inf...

https://rxivist.org/papers/106996
https://doi.org/10.1101/2020.02.22.20025320

12: Protein Classifier for Thyroid Nodules Learned from Rapidly Acquired Proteotypes

Yaoting Sun, Sathiyamoorthy Selvarajan et al.

1,935 downloads (posted 14 Apr 2020)

Up to 30% of thyroid nodules cannot be accurately classified as benign or malignant by cytopathology. Diagnostic accuracy can be improved by nucleic acid-based testing, yet a sizeable number of diagnostic thyroidectomies remains unavoidable. In order to develop a protein classifier for thyroid nodules, we analyzed the quantitative proteomes of 1,725 retrospective thyroid tissue samples from 578 patients using pressure-cycling technology and data-independent acquisition mass spectrometry. With artificial neural networks,...

https://rxivist.org/papers/108572
https://doi.org/10.1101/2020.04.09.20059741

13: The impact of the COVID-19 pandemic on quality of life, physical and psychosocial wellbeing in breast cancer patients and survivors - A prospective, multicenter cohort study

Claudia A Bargon, Marilot CT Batenburg et al.

1,934 downloads (posted 28 Jun 2020)

Purpose: The COVID-19 pandemic and the resulting social distancing and lockdown measures are having a substantial impact on daily life and medical management of people with breast cancer. We evaluated to what extent these changes have affected quality of life and physical, and psychosocial wellbeing of people (being) treated for breast cancer. Methods: This study was conducted within the prospective Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA). Shortly after the impl...

https://rxivist.org/papers/113158
https://doi.org/10.1101/2020.06.26.20140657

14: SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy

Lova Sun, Sanjna Surya et al.

1,858 downloads (posted 16 Jan 2021)

Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to f...

https://rxivist.org/papers/125484
https://doi.org/10.1101/2021.01.15.21249810

15: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Bo Wang, Oliver Van Oekelen et al.

1,830 downloads (posted 05 Jun 2020)

Background: The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma (MM) population. Herein, we report the characteristics of COVID-19 infection and serological response in MM patients in a large tertiary care institution in New Yo...

https://rxivist.org/papers/112031
https://doi.org/10.1101/2020.06.04.20122846

16: Factors affecting COVID-19 outcomes in cancer patients - A first report from Guys Cancer Centre in London

Beth Russell, Charlotte Moss et al.

1,724 downloads (posted 19 May 2020)

Background: There is insufficient evidence to support clinical decision-making for cancer patients diagnosed with COVID-19 due to the lack of large studies. Methods: We used data from a single large UK Cancer Centre to assess demographic/clinical characteristics of 156 cancer patients with a confirmed COVID-19 diagnosis between 29 February-12 May 2020. Logistic/Cox proportional hazards models were used to identify which demographic and/or clinical characteristics were associated with COVID-19 severity/death. Results: 12...

https://rxivist.org/papers/110805
https://doi.org/10.1101/2020.05.12.20094219

17: A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China

Hongyan Zhang, Linwei Wang et al.

1,707 downloads (posted 26 Mar 2020)

OBJECTIVETo study clinical characteristics of cancer patients infected with COVID-19. Outcomes of cancer patients were the key contents of this study. DESIGNRetrospective study. SETTINGFour designated COVID-16 hospitals in Wuhan, Hubei province, China. PARTICIPANTSMedical records of 67 cancer patients admitted to hospitals between Jan 5, 2020 to Feb 18, 2020 were included. MAIN OUTCOME MEASURESDemographic, clinical, laboratory, radiological and treatment data were collected. Survival data of the cohort was cut-off o...

https://rxivist.org/papers/107767
https://doi.org/10.1101/2020.03.21.20037127

18: Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors

Andrew A. Davis, Wade T. Iams et al.

1,682 downloads (posted 24 Jul 2019)

PurposeTreatment response assessment for patients with advanced solid tumors is complex and existing methods of assessment require greater precision for early disease assessment. Current guidelines rely on imaging, which has limitations such as the long time required before treatment effectiveness can be determined. Serial changes in whole-genome (WG) circulating tumor DNA (ctDNA) were used to detect disease progression early in the treatment course. Methods97 patients with advanced cancer were enrolled, and blood was ...

https://rxivist.org/papers/105715
https://doi.org/10.1101/19002550

19: Post-Exertional Malaise in People with Chronic Cancer-Related Fatigue

Rosemary Twomey, Samuel T. Yeung et al.

1,598 downloads (posted 15 Dec 2019)

ContextCancer-related fatigue (CRF) is a distressing and persistent sense of tiredness or exhaustion that interferes with usual functioning. Chronic CRF continues for months after curative cancer treatment is complete. Post-exertional malaise (PEM) is a worsening of symptoms after physical or mental activity, with limited investigations in people with chronic CRF. ObjectivesThe purpose of this study was to identify and describe self-reported incidences of PEM in people with chronic CRF. MethodsParticipants (n=18) were...

https://rxivist.org/papers/106423
https://doi.org/10.1101/2019.12.12.19014829

20: Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors

Adam C. Palmer, Benjamin Izar et al.

1,451 downloads (posted 04 Feb 2020)

Hundreds of clinical trials are testing whether combination therapies can increase the anti-tumor activity of Immune Checkpoint Inhibitors (ICIs). We find that the benefits of recently reported and approved combinations involving ICIs are fully accounted for by increasing the chance of a single-agent response (drug independence), with no requirement for additive or synergistic efficacy. Thus, the degree of success of combinations involving ICIs with other therapies is largely predictable.

https://rxivist.org/papers/106766
https://doi.org/10.1101/2020.01.31.20019604